Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-κB pathway

Lipids in Health and Disease

Baomin Li²  Aili Ge²  Yudong Ma²  Lu Sun¹  Chen Wu²  Yanfang Si³  Jun Wang² 

[1] Department of Pathology, the General Hospital of PLA, Beijing, 100853, China;Department of Neurosurgery, the General Hospital of PLA, Beijing, 100853, China;Department of Ophthalmology, the 309th Hospital of Chinese PLA, Beijing, 100091, China

关键词: Toll-like receptor 4;    Adventitial fibroblasts;    Atherosclerosis;    ADRP;    Lipid accumulation;    LPS;   

Others  :  1160174
DOI  :  10.1186/1476-511X-11-139

 received in 2012-06-19, accepted in 2012-09-30,  发布年份 2012

【 摘 要 】

Background

Atherosclerosis is a chronic degenerative disease of the arteries and is thought to be one of the most common causes of death globally. In recent years, the functions of adventitial fibroblasts in the development of atherosclerosis and tissue repair have gained increased interests. LPS can increase the morbidity and mortality of atherosclerosis-associated cardiovascular disease. Although LPS increases neointimal via TLR4 activation has been reported, how LPS augments atherogenesis through acting on adventitial fibroblasts is still unknown. Here we explored lipid deposition within adventitial fibroblasts mediated by lipopolysaccharide (LPS) to imitate inflammatory conditions.

Results

In our study, LPS enhanced lipid deposition by the up-regulated expression of adipose differentiation-related protein (ADRP) as the silencing of ADRP abrogated lipid deposition in LPS-activated adventitial fibroblasts. In addition, pre-treatment with anti-Toll-like receptor 4 (TLR4) antibody diminished the LPS-induced lipid deposition and ADRP expression. Moreover, LPS induced translocation of nuclear factor-κB(NF-κB), which could markedly up-regulate lipid deposition as pre-treatment with the NF-κB inhibitor, PDTC, significantly reduced lipid droplets. In addition, the lowering lipid accumulation was accompanied with the decreased ADRP expression. Furthermore, LPS-induced adventitial fibroblasts secreted more monocyte chemoattractant protein (MCP-1), compared with transforming growth factor-β1 (TGF-β1).

Conclusions

Taken together, these results suggest that LPS promotes lipid accumulation via the up-regulation of ADRP expression through TLR4 activated downstream of NF-κB in adventitial fibroblasts. Increased levels of MCP-1 released from LPS-activated adventitial fibroblasts and lipid accumulation may accelerate monocytes recruitment and lipid-laden macrophage foam cells formation. Here, our study provides a new explanation as to how bacterial infection contributes to the pathological process of atherosclerosis.

【 授权许可】

   
2012 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
• [2]Ounpuu S, Negassa A, Yusuf S: INTER-HEART: A global study of risk factors for acute myocardial infarction. Am Heart J 2001, 141:711-721.
• [3]Yusuf S, Ôunpuu S, Anand S: The global epidemic of atherosclerotic cardiovascular disease. Medical Principles and Practice 2002, 11:3-8.
• [4]Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
• [5]Haurani MJ, Cifuentes ME, Shepard AD, Pagano PJ: Nox4 Oxidase Overexpression Specifically Decreases Endogenous Nox4 mRNA and Inhibits Angiotensin II–Induced Adventitial Myofibroblast Migration. Hypertension 2008, 52:143-149.
• [6]Liu ZY, Kong W: The role of adventitia in atherosclerosis. Sheng Li Ke Xue Jin Zhan 2010, 41:177-182.
• [7]Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
• [8]Recinos A, LeJeune WS, Sun H, Lee CY, Tieu BC, Lu M, Hou T, Boldogh I, Tilton RG, Brasier AR: Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis 2007, 194:125-133.
• [9]Wang XP, Chen YG, Qin WD, Zhang W, Wei SJ, Wang J, Liu FQ, Gong L, An FS, Zhang Y, et al.: Arginase I attenuates inflammatory cytokine secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011, 31:1853-1860.
• [10]Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M: Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001, 22:199-204.
• [11]Ostos MA, Recalde D, Zakin MM, Scott-Algara D: Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002, 519:23-29.
• [12]Kallio KA, Buhlin K, Jauhiainen M, Keva R, Tuomainen AM, Klinge B, Gustafsson A, Pussinen PJ: Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun 2008, 14:247-253.
• [13]Lehr HA, Sagban TA, Ihling C, Zähringer U, Hungerer KD, Blumrich M, Reifenberg K, Bhakdi S: Immunopathogenesis of Atherosclerosis Endotoxin Accelerates Atherosclerosis in Rabbits on Hypercholesterolemic Diet. Circulation 2001, 104:914-920.
• [14]Vink A, Schoneveld AH, van der Meer JJ, Van Middelaar BJ, Sluijter JPG, Smeets MB, Quax PHA, Lim SK, Borst C, Pasterkamp G: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002, 106:1985-1990.
• [15]Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004, 101:10679-10684.
• [16]Kim S, Park J, Kim K, Lee W, Kim K, Park K: Melittin Inhibits Atherosclerosis in LPS/High-Fat Treated Mice Through Atheroprotective Actions. J Atheroscler Thromb 2011, 18:1117-1126.
• [17]Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S: More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome–sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107.
• [18]Miyazawa T, Nakagawa K, Shimasaki S, Nagai R: Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids 2012, 42:1163-1170.
• [19]Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004, 291:1071-1080.
• [20]Paul A, Chang BHJ, Li L, Yechoor VK, Chan L: Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circ Res 2008, 102:1492-1501.
• [21]Feng X, Zhang Y, Xu R, Xie X, Tao L, Gao H, Gao Y, He Z, Wang H: Lipopolysaccharide up-regulates the expression of Fcα/μ receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 2010, 208:396-405.
• [22]Tieu BC, Ju X, Lee C, Sun H, Lejeune W, Recinos A, Brasier AR, Tilton RG: Aortic adventitial fibroblasts participate in angiotensin-induced vascular wall inflammation and remodeling. J Vasc Res 2011, 48:261-272.
• [23]Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR: Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-κB dependent inflammatory response. Cardiovasc Res 2006, 72:384-393.
• [24]Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
• [25]Schürch W, Seemayer TA, Gabbiani G: The myofibroblast: a quarter century after its discovery. Am J Surg Pathol 1998, 22:141-147.
• [26]Simonin MA, Bordji K, Boyault S, Bianchi A, Gouze E, Becuwe P, Dauca M, Netter P, Terlain B: PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 2002, 282:C125-C133.
• [27]Takada H, Mihara J, Morisaki I, Hamada S: Induction of interleukin-1 and-6 in human gingival fibroblast cultures stimulated with Bacteroides lipopolysaccharides. Infect Immun 1991, 59:295-301.
• [28]Sawayama Y, Hamada M, Otaguro S, Maeda S, Ohnishi H, Fujimoto Y, Taira Y, Hayashi J: Chronic Helicobacter pylori infection is associated with peripheral arterial disease. J Infect Chemother 2008, 14:250-254.
• [29]Kalay N, Kutukoglu I, Ozdogru I, Kilic H, Cetinkaya Y, Eryol N, Karakaya E, Oguzhan A: The relationship between Chlamydophila pneumoniae IgG titer and coronary atherosclerosis. Cardiol J 2008, 15:245-251.
• [30]Xu Q: Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:1547-1559.
• [31]Melián A, Geng YJ, Sukhova GK, Libby P, Porcelli SA: CD1 expression in human atherosclerosis: a potential mechanism for T cell activation by foam cells. Am J Pathol 1999, 155:775-786.
• [32]Ball R, Stowers E, Burton J, Cary N, Skepper J, Mitchinson M: Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995, 114:45-54.
• [33]Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW: Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001, 21:2011-2018.
• [34]O’Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A: Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519-527.
• [35]Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, Takahashi M, Tazoe F, Wada T, Ohta K, et al.: Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis. Cell Metab 2009, 10:219-228.
• [36]Upston JM, Niu X, Brown AJ, Mashima R, Wang H, Senthilmohan R, Kettle AJ, Dean RT, Stocker R: Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 2002, 160:701-710.
• [37]MacTaggart JN, Xiong W, Knispel R, Baxter BT: Deletion of CCR2 but not CCR5 or CXCR3 inhibits aortic aneurysm formation. Surgery 2007, 142:284-288.
• [38]Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004, 94:1203-1210.
• [39]Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773-778.
• [40]Kim WJH, Chereshnev I, Gazdoiu M, Fallon JT, Rollins BJ, Taubman MB: MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem Biophys Res Commun 2003, 310:936-942.
• [41]Szardening-Kirchner C, Konrad L, Hauck EW, Haag SM, Eickelberg O, Weidner W: Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie’s disease. World J Urol 2009, 27:123-130.
• [42]Moon SK, Woo JI, Lee HY, Park R, Shimada J, Pan H, Gellibolian R, Lim DJ: Toll-like receptor 2-dependent NF-κB activation is involved in nontypeable Haemophilus influenzae-induced monocyte chemotactic protein 1 up-regulation in the spiral ligament fibrocytes of the inner ear. Infect Immun 2007, 75:3361-3372.
• [43]Remppis A, Bea F, Greten HJ, Buttler A, Wang H, Zhou Q, Preusch MR, Enk R, Ehehalt R, Katus H, Blessing E: Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm 2010, 2010:194896.
• [44]Calzado MA, Bacher S, Schmitz ML: NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007, 14:367-376.